Clinical trial · no report yet · Phase 3
FIGHT-302
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
- NCT03656536 ↗
- Terminated
- Incyte Corporation
- 26 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 18 | |
| YouTube | 5 | |
| Podcasts | 2 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma
- Interventions
- Pemigatinib; Gemcitabine; Cisplatin
- Arms
- Pemigatinib · Experimental
- Gemcitabine + Cisplatin · Active comparator
- Enrollment
- 167
- Primary outcomes
- Randomized Treatment Period: Progression-free Survival (PFS)
- Randomized Treatment Period: Kaplan-Meier Estimates of PFS of the Indicated Lengths of Time
- Transition Period: PFS
- Transition Period: Kaplan-Meier Estimates of PFS of the Indicated Lengths of Time
- Sponsor
- Incyte Corporation
- Start
- Jun 3, 2019
- Primary completion
- Jul 7, 2025
- Results posted
- Yes
- Registry record
- NCT03656536 · updated Aug 11, 2026
Publications
linked from the registry- Bekaii-Saab TS, Melisi D, Wilmink H, Garufi C, Tran N, Tortora G, De Braud F, Frodin JE, Lonardi S, Lin E, Babiker H, Lin B, Fornaro L, Munoz Martin A, Bridgewater J, Knox JJ, De Vos-Geelen J, Scott-Brown M, Veronese L, Ioannidis S, Gilmartin A, Janik JE, Guo Y, Furuse J, Ioka T, Rimassa L, Vogel A. Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial. J Clin Oncol. 2026 Jun 1:JCO2600788. doi: 10.1200/JCO-26-00788. Online ahead of print. PubMed 42223137
- Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater J, Wasan H, Borad MJ, Abou-Alfa GK, Jiang P, Lihou CF, Zhen H, Asatiani E, Feliz L, Vogel A. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol. 2020 Oct;16(30):2385-2399. doi: 10.2217/fon-2020-0429. Epub 2020 Jul 17. PubMed 32677452